A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity

Nature

Volumn 414, Issue 6860, 2001, Pages 212-216

  Weggen, Sascha ^a   Eriksen, Jason L ^b   Das, Pritam ^b   Sagi, Sarah A ^a   Wang, Rong ^c   Pietrzik, Claus U ^a   Findlay, Kirk A ^b   Smith, Tawnya E ^b   Murphy, Michael P ^b   Bulter, Thomas ^d   Kang, David E ^a   Marquez Sterling, Numa ^e   Golde, Todd E ^b   Koo, Edward H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d California Institute of Technology   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; DISEASES; DRUG DOSAGE; EPIDEMIOLOGY; PATHOLOGY;

INFLAMMATORY RESPONSES;

ENZYME KINETICS;

IBUPROFEN; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; SULINDAC;

MEDICINE;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL CELL; ARTICLE; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPARTIC ENDOPEPTIDASES; BRAIN; CHO CELLS; CRICETINAE; DISEASE MODELS, ANIMAL; ENDOPEPTIDASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IBUPROFEN; INDOMETHACIN; MASS SPECTROMETRY; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULINDAC; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0035829592     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/35102591     Document Type: Article

References (30)

1. Inflammation and Alzheimer's disease
2. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies
3. Clinical trial of indomethacin in Alzheimer's disease
4. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: The Cache County study
5. Risk of Alzheimer's disease and duration of NSAID use
6. Cyclooxygenases: Structural, cellular, and molecular biology
7. The role of Aβ42 in Alzheimer's disease
8. Presenilin 1 regulates pharmacologically distinct γ-secretase activities. Implications for the role of presenilin in γ-secretase cleavage
9. Chemoprevention of colorectal cancer
10. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease
11. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction
12. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs
13. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSADs) on cyclooxygenase-null embryo fibroblasts
14. Inhibition of prostaglandin synthesis in rat brain
15. Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1
16. A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain
17. γ-secretase inhibitors repress thymocyte development
18. Neurotoxicity ofa fragment of the amyloid precursor associated with Alzheimer's disease
19. Age-dependent neuronal and synaptic degeneration in mice transgenic for the C terminus of the amyloid precursor protein
20. Mutagenesis identifies new signals for β-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Aβ 42
21. Signal transduction by activated mNotch: Importance of proteolytic processing and its regulation by the extracellular domain
22. Improved electrophoretic separation and immunoblotting of β-amyloid (Aβ) peptides 1-40, 1-42, and 1-43
23. Insulin-degrading enzyme regulates extracellular extracellular levels of amyloid β-protein by degradation
24. 1-42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition
25. Modulation of amyloid β-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway
26. Cyclo-oxygenase-2 inhibitors: Rationale and therapeutic potential for Alzheimer's disease
27. Recombinant adenovirus is an appropriate vector for endocytotic protein trafficking studies in cultured neurons
28. The profile of soluble amyloid β protein in cultured cell media. Detection and quantification of amyloid β protein and variants by immunoprecipitation mass spectrometry
29. Age-dependent changes in brain, CSF, and plasma amyloid (β) protein in the Tg2576 transgenic mouse model of Alzheimer's disease